Online platforms

This subtopic contains guidance on EU level rules relating to online platforms.

Practice Note: Online platforms in the EU—introduction looks at key definitions and terms used to describe platform solutions, and gives an explanation of the common types of platform and terms associated with them, including online market places, streaming media platforms, social media platforms, video-sharing platform services, search engines, online instant messaging services and video communication/conferencing platforms. It also includes an explanation of the definitions, in each of the key pieces of legislation in the EU, used to determine the entities caught within the scope of that legislation, in most cases being the definition of intermediaries or intermediary services.

As the role of platforms becomes evermore pivotal in facilitating e-commerce, data exchange and social interaction, the EU legislative framework governing them is under assessment and revision. Platform providers need to keep a close eye on emerging regulations to ensure that they remain compliant.

The EU Geo-blocking Regulation

Regulation (EU) 2018/302 on addressing unjustified geo-blocking and other forms of discrimination based on customers' nationality, place of residence or place of establishment within the

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

Commission publishes updated clinical trials guidance package

The European Commission's Directorate-General for Health and Food Safety has published a comprehensive package of updated clinical trials guidance documents, all endorsed by the Clinical Trials Coordination and Advisory Group (CTAG) on 15 October 2025. The package includes new recommendations on criteria for selecting a reporting Member State under Article 85(2)(c) of the Clinical Trials Regulation, establishing a workshare criterion when proposed reporting Member States decline the role, which occurs in approximately 30% of applications. The Commission has updated its recommendation paper on decentralised elements in clinical trials (Version 02), superseding the December 2022 version, with revised national provision overviews and guidance on informed consent, investigational medicinal product delivery, and remote monitoring. A new recommendation paper addresses frequent issues identified during Part I and Part II assessments, based on feedback from national competent authorities and ethics committees, covering investigational medicinal product dossiers, protocols, and safety reporting. The package also includes revised guidance on auxiliary medicinal products, effective 1 December 2025 for new applications, featuring an updated classification system distinguishing between authorised, modified authorised, and unauthorised auxiliary medicinal products with corresponding application and safety reporting requirements.

View EU Law by content type :

Popular documents